News

US FDA approves Nuvation Bio's lung cancer therapy
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...
Nuvation Bio: Judgement Day Grows Closer
Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...
PMLive1d
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...
pharmaphorum1d
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...
Contract Pharma1d
U.S. FDA Approves Nuvation Bio’s Ibtrozi
Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...
The American Journal of Managed Care2d
Taletrectinib Approved for ROS1-Positive NSCLC
This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...
The Pharma Letter1d
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...
US FDA approves Nuvation Bio's rare lung cancer drug
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...